RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Basilea Pharmaceutica AG Allschwil Stock

Basilea Pharmaceutica AG Allschwil Liabilities 2024

Basilea Pharmaceutica AG Allschwil Liabilities

183.29 M CHF

Ticker

BSLN.SW

ISIN

CH0011432447

WKN

A0B9GA

In 2024, Basilea Pharmaceutica AG Allschwil's total liabilities amounted to 183.29 M CHF, a -24.12% difference from the 241.56 M CHF total liabilities in the previous year.

Basilea Pharmaceutica AG Allschwil Aktienanalyse

What does Basilea Pharmaceutica AG Allschwil do?

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Basilea Pharmaceutica AG Allschwil's Liabilities

Basilea Pharmaceutica AG Allschwil's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Basilea Pharmaceutica AG Allschwil's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Basilea Pharmaceutica AG Allschwil's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Basilea Pharmaceutica AG Allschwil's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Basilea Pharmaceutica AG Allschwil’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock

What is the level of liabilities of Basilea Pharmaceutica AG Allschwil this year?

Basilea Pharmaceutica AG Allschwil has a debt balance of 183.29 M CHF this year.

What were the liabilities of Basilea Pharmaceutica AG Allschwil compared to the previous year?

The liabilities of Basilea Pharmaceutica AG Allschwil have increased by -24.12% dropped compared to the previous year.

What are the consequences of high debt for investors of Basilea Pharmaceutica AG Allschwil?

High liabilities can pose a risk for investors of Basilea Pharmaceutica AG Allschwil, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Basilea Pharmaceutica AG Allschwil?

Low liabilities mean that Basilea Pharmaceutica AG Allschwil has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Basilea Pharmaceutica AG Allschwil affect the company?

An increase in liabilities of Basilea Pharmaceutica AG Allschwil can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Basilea Pharmaceutica AG Allschwil affect the company?

A decrease in the liabilities of Basilea Pharmaceutica AG Allschwil can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Basilea Pharmaceutica AG Allschwil?

Some factors that can influence the liabilities of Basilea Pharmaceutica AG Allschwil include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Basilea Pharmaceutica AG Allschwil so important for investors?

The liabilities of Basilea Pharmaceutica AG Allschwil are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Basilea Pharmaceutica AG Allschwil take to modify the liabilities?

To change its liabilities, Basilea Pharmaceutica AG Allschwil can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.42 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.42 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.